![Haartopener_0](https://www.hivplusmag.com/media-library/haartopener-0.jpg?id=32665765&width=1200&height=1002)
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Over 4,700 Kenyan and Ugandan heterosexual serodiscordant couples'in which one partner is HIV-positive and the other is negative'took part in a recent trial studying the effectiveness of pre-exposure prophylaxis, a.k.a. PrEP, the use of HIV medication by those who are not HIV-positive as a prevention measure. One third of uninfected partners were given a placebo, another third the drug tenofovir (Viread), and the final third took Truvada, a pill that contains tenofovir and the drug emtricitabine. The results, released in July, were staggering: Compared to those on the placebo, those taking tenofovir had a 62% lower transmission rate, and the Truvada users had 73% fewer transmissions. Researchers behind the study, sponsored by the University of Washington, stopped the trial, declared the PrEP therapy an unequivocal benefit, and distributed the drugs to all participants. Another recent study, sponsored by the U.S. Centers for Disease Control and Prevention, distributed Truvada to certain high-risk heterosexual HIV-negative individuals in Botswana. Although that study had a smaller focus group of 1,200 participants, the numbers were still extremely encouraging, with 62% fewer new HIV cases among those receiving the drug than those given a placebo. Back in America, many hope the results will eventually lead to Truvada distribution to all serodiscordant couples and other high-risk individuals. Recent studies have already shown that the PrEP therapy is effective in transgender women and men who have sex with men. But Mitchell Warren, the executive director of the New York'based AIDS Vaccine Advocacy Coalition, says widespread distribution of Truvada will likely happen overnight. There are two reasons for restraint, according to Warren. First, the two successful studies follow a trial that was stopped for the complete opposite reason that the recent couples' trial was halted'the drug didn't seem to work with high-risk heterosexual African women. Second, budgets are an issue. As AIDS Drug Assistance Programs are cut across the country, it's hard to conceive of states having the money to distribute Truvada widely. 'There's a kind of champagne celebration on one hand and a hangover on the other, because there's a tremendous burden on our system on how to implement this,' Warren says. The issue of cost is one that's already being addressed, according to a report from Project Inform, a San Francisco-based HIV organization. Following the successful trials featuring PrEP and gay men, the CDC began initiating discussions with insurers, some of which demonstrated 'a willingness to reimburse PrEP in the limited circumstances described by the CDC's interim guidance,' while Gilead, the maker of Truvada, has shown interest in implementing a patient assistance program akin to ADAPs, which are currently used by tens of thousands of people. Lisa Sterman, a San Francisco'based physician and board member for the San Francisco AIDS Foundation, is convinced of Truvada's benefit and already prescribes it to high-risk patients. While she's careful to ask potential users about diabetes history and kidney problems'conditions she says can be exacerbated by Truvada'Sterman believes the drug is a no-brainer for those regularly exposed to HIV and that the unsuccessful PrEP trial likely failed because of spotty adherence. '[PrEP] works if people comply with it,' she says. 'I think it works 99% of the time if used properly.'
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
'Drag Race' star Q shares she's living with HIV
March 18 2024 3:08 PM
Plus: Featured Video
Latest Stories
La ciencia detrás de U=U ha estado liberando a las personas con VIH durante años
August 23 2024 2:48 PM
Tratamiento y prevención del VIH por inyección: Todo lo que necesita saber
August 23 2024 2:41 PM
Sr. Gay World quiere asegurarse de que estés bien
August 23 2024 2:30 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
With a new case in Sweden, what is the new mpox outbreak and should you be concerned?
August 15 2024 4:48 PM
The freedom of disclosure: David Anzuelo's journey through HIV, art, and advocacy
August 02 2024 12:21 PM
From ‘The Real World’ to real life: How Danny Roberts thrives with HIV
July 31 2024 5:23 PM
The July/Aug 'Treatment Guide' issue of Plus is here!
June 26 2024 3:49 PM
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM